Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $20.00 at Piper Sandler

Sarepta Therapeutics (NASDAQ:SRPT) had its target price cut by Piper Sandler from $23.00 to $20.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock.

A number of other research firms also recently commented on SRPT. Wall Street Zen upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, July 4th. Weiss Ratings cut Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, June 29th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Sarepta Therapeutics from $12.00 to $14.00 and gave the stock a “sell” rating in a research report on Thursday, March 26th. Royal Bank Of Canada lifted their price target on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a research report on Tuesday, April 7th. Finally, Needham & Company LLC reiterated an “underperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, March 26th. Nine equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and seven have assigned a Sell rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics has a consensus rating of “Hold” and a consensus price target of $25.09.

Sarepta Therapeutics Stock Up 1.5%

Shares of SRPT opened at $20.52 on Thursday. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $25.32. The company’s fifty day moving average is $17.79 and its two-hundred day moving average is $19.29. The firm has a market cap of $2.17 billion, a PE ratio of -21.38, a price-to-earnings-growth ratio of 0.21 and a beta of 0.21. The company has a quick ratio of 2.62, a current ratio of 4.63 and a debt-to-equity ratio of 0.56.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, topping the consensus estimate of $0.98 by $2.18. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The business had revenue of $730.80 million for the quarter, compared to analyst estimates of $474.15 million. During the same period last year, the company posted ($3.42) EPS. The business’s quarterly revenue was down 1.9% on a year-over-year basis. Analysts forecast that Sarepta Therapeutics will post 3.95 earnings per share for the current year.

Institutional Trading of Sarepta Therapeutics

Large investors have recently modified their holdings of the business. Yousif Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 1.9% in the 4th quarter. Yousif Capital Management LLC now owns 25,704 shares of the biotechnology company’s stock valued at $541,000 after purchasing an additional 481 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Sarepta Therapeutics by 7.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock worth $190,000 after acquiring an additional 636 shares in the last quarter. Thrivent Financial for Lutherans grew its position in shares of Sarepta Therapeutics by 3.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after acquiring an additional 744 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Sarepta Therapeutics by 1.8% in the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company’s stock valued at $829,000 after acquiring an additional 758 shares during the last quarter. Finally, Larson Financial Group LLC increased its holdings in shares of Sarepta Therapeutics by 82.5% in the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 851 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.